3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
57
Carcinoma, Non-Small-Cell Lung
30
Breast Neoplasms
26
Neoplasms
24
Neoplasm Metastasis
24
Triple Negative Breast Neoplasms
21
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Lung Neoplasms
9
Melanoma
8
Stomach Neoplasms
7
Carcinoma, Pancreatic Ductal
7
Adenocarcinoma
7
Ovarian Neoplasms
6
Colorectal Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
4
Esophageal Neoplasms
4
Digestive System Neoplasms
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Small Cell Lung Carcinoma
3
Sarcoma
3
Recurrence
3
Rectal Neoplasms
3
Pancreatic Diseases
3
Neoplasms by Site
3
Lymphoma, Non-Hodgkin
3
Fallopian Tube Neoplasms
3
Endometrial Neoplasms
3
Endocrine Gland Neoplasms
3
Digestive System Diseases
3
Interventions
tremelimumab
1
durvalumab
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Non Small Cell Lung Cancer NSCLC
×
Albumin-Bound Paclitaxel
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA